Non-Current Assets
Other intangible assets—net
Bristol-Myers Squibb Other intangible assets—net decreased by 18.0% to $19.10B in Q4 2025 compared to the prior quarter.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Assets
CategoryMarket Position
SignalContext dependent
VolatilityModerate
First reportedQ4 2025
Last reportedQ1 2026
How to read this metric
An increase typically follows acquisitions, while a steady decrease reflects ongoing amortization of existing intangible assets.
Detailed definition
This represents the net book value of identifiable non-physical assets such as acquired technology, patents, customer li...
Peer comparison
Standard for companies that grow through M&A, often labeled 'Intangible assets, net'.
Metric ID:
non_current_assets_intangible_assets_net_excluding_goodwillHistorical Data
2 periods
| Q4 '24 | Q4 '25 | |
|---|---|---|
| Value | $23.31B | $19.10B |
| QoQ Change | — | -18.0% |
| YoY Change | — | -18.0% |
Range$19.10B – $23.31B
Avg YoY Growth-18.0%
Median YoY Growth-18.0%
Other intangible assets—net at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's other intangible assets—net?
- Bristol-Myers Squibb (BMY) reported other intangible assets—net of $19.10B in Q4 2025.
- What does other intangible assets—net mean?
- The value of non-physical assets like patents and acquired technology, excluding goodwill.